Drug intelligence / Profile preview

Inovocox

Development stage: Unknown
Lead developer: Pfizer
Modality: Vaccines & Immunotherapeutics
Administration: Oral, Parenteral

Overview

**Inovocox** is a USDA-licensed veterinary live oocyst vaccine for prevention of coccidiosis in broiler chickens. It contains live oocysts of *Eimeria acervulina*, *Eimeria maxima*, and *Eimeria tenella*; the original formulation included two *E. maxima* strains. Administered in ovo to 18- to 19-day embryonated chicken eggs or orally to day-old chickens, it exposes birds to coccidia early in life and induces protective active immunity against subsequent intestinal infection. The product was originated by Embrex, subsequently developed by Pfizer Animal Health and Zoetis, and is currently marketed and manufactured by Huvepharma. ([huvepharma.us](https://www.huvepharma.us/wp-content/uploads/2021/04/Inovocox-insert-single-tier-56010000.04_.pdf))

Brand names: Inovocox

Beyond the preview

Go deeper on Inovocox.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inovocox.

Explore the full profile